|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
|
US7588766B1
(en)
|
2000-05-26 |
2009-09-15 |
Elan Pharma International Limited |
Treatment of amyloidogenic disease
|
|
US6761888B1
(en)
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
|
US7790856B2
(en)
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
|
HK1043312B
(en)
|
1999-05-07 |
2006-07-28 |
Genentech, Inc. |
Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
|
|
DK2314315T3
(en)
|
1999-06-01 |
2015-02-02 |
Biogen Idec Inc |
Blocking monoclonal antibody to the human alpha1-I domain of VLA-1 and their use for the treatment of inflammatory diseases
|
|
KR20020091170A
(ko)
|
2000-03-31 |
2002-12-05 |
아이덱 파마슈티칼즈 코포레이션 |
Ｂ 세포 림프종의 치료를 위한 항-사이토카인 항체 또는길항제 및 항-ｃｄ２０의 조합된 사용
|
|
EP1935431A3
(de)
|
2000-05-15 |
2008-08-13 |
Health Research, Inc. |
Krebsbehandlungen unter Verwendung einer Kombination aus einem HER2-Antikörper und Interleukin-2
|
|
JP5155502B2
(ja)
*
|
2000-06-20 |
2013-03-06 |
雪印メグミルク株式会社 |
鉄含有タンパク質組成物
|
|
EP1299128A2
(de)
|
2000-06-20 |
2003-04-09 |
Idec Pharmaceuticals Corporation |
Kaltes anti-cd20 antikörper/radiomarkiertes anti-cd22 antikörper kombination
|
|
US8632778B2
(en)
|
2000-08-11 |
2014-01-21 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilized anti-interleukin-6 antibody-containing preparations
|
|
JP2002075937A
(ja)
|
2000-08-30 |
2002-03-15 |
Nitto Denko Corp |
半導体ウエハの加工方法
|
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
|
EP1383532B1
(de)
|
2001-04-02 |
2011-05-04 |
Genentech, Inc. |
Kombinationstherapie
|
|
MXPA03009390A
(es)
|
2001-04-13 |
2004-01-29 |
Biogen Inc |
Anticuerpos para integrina vla-1.
|
|
EP1391209A4
(de)
*
|
2001-05-30 |
2009-12-16 |
Chugai Pharmaceutical Co Ltd |
Proteinzubereitung
|
|
GB0113179D0
(en)
*
|
2001-05-31 |
2001-07-25 |
Novartis Ag |
Organic compounds
|
|
CA2385745C
(en)
|
2001-06-08 |
2015-02-17 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
|
WO2003009817A2
(en)
*
|
2001-07-25 |
2003-02-06 |
Protein Design Labs, Inc. |
Stable lyophilized pharmaceutical formulation of igg antibodies
|
|
EP1427744B1
(de)
|
2001-08-27 |
2007-12-26 |
Genentech, Inc. |
System zur antikörperexpression und- synthese
|
|
IL161677A0
(en)
*
|
2001-11-08 |
2004-09-27 |
Protein Design Labs |
Stable liquid pharmaceutical formulation of igg antibodies
|
|
WO2003068260A1
(fr)
*
|
2002-02-14 |
2003-08-21 |
Chugai Seiyaku Kabushiki Kaisha |
Produits pharmaceutiques en solution contenant des anticorps
|
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
|
DK1507556T3
(en)
|
2002-05-02 |
2016-09-12 |
Wyeth Holdings Llc |
Calicheamicin derivative-carrier conjugates
|
|
GB0210121D0
(en)
|
2002-05-02 |
2002-06-12 |
Celltech R&D Ltd |
Biological products
|
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
|
MY150740A
(en)
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
|
ES2347241T3
(es)
|
2002-12-16 |
2010-10-27 |
Genentech, Inc. |
Variantes de inmunoglobulina y sus utilizaciones.
|
|
NO346070B1
(no)
|
2003-02-10 |
2022-01-31 |
Biogen Ma Inc |
Stabil, vandig, farmasøytisk formulering og fremgangsmåte for fremstilling derav.
|
|
EP2062916A3
(de)
|
2003-04-09 |
2009-08-19 |
Genentech, Inc. |
Autoimmunerkrankungstherapie eines Patienten mit unzureichender Reaktion auf einen TNF-alpha-Inhibitor
|
|
WO2005000901A2
(en)
|
2003-05-09 |
2005-01-06 |
Duke University |
Cd20-specific antibodies and methods of employing same
|
|
TWI306458B
(en)
|
2003-05-30 |
2009-02-21 |
Elan Pharma Int Ltd |
Humanized antibodies that recognize beta amyloid peptide
|
|
AU2004256042A1
(en)
|
2003-06-05 |
2005-01-20 |
Genentech, Inc. |
BlyS antagonists and uses thereof
|
|
EP2236172A1
(de)
|
2003-11-04 |
2010-10-06 |
Novartis Vaccines and Diagnostics, Inc. |
Kombinationstherapie mit anti-CD20 und anti-CD40 Antikörper zur Behandlung von B-Zell Krebsarten
|
|
EP2243491A1
(de)
|
2003-11-04 |
2010-10-27 |
Novartis Vaccines and Diagnostics, Inc. |
Verwendung von antagonistischen anti-CD40-Antikörpern zur Behandlung von chronischer lymphatischer Leukämie
|
|
PL1680141T3
(pl)
|
2003-11-04 |
2011-04-29 |
Novartis Vaccines & Diagnostics Inc |
Sposoby leczenia guzów litych wykazujących ekspresję antygenu powierzchniowego CD40
|
|
DK1684805T3
(da)
|
2003-11-04 |
2010-10-04 |
Novartis Vaccines & Diagnostic |
Anvendelse af antagonist anti-CD40-monoklonale antistoffer til behandling af multipel myeloma
|
|
SG148143A1
(en)
|
2003-11-04 |
2008-12-31 |
Novartis Vaccines & Diagnostic |
Antagonist anti-cd40 monoclonal antibodies and methods for their use
|
|
ES2672640T3
(es)
|
2003-11-05 |
2018-06-15 |
Roche Glycart Ag |
Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
|
|
US20050136055A1
(en)
*
|
2003-12-22 |
2005-06-23 |
Pfizer Inc |
CD40 antibody formulation and methods
|
|
US20070184050A1
(en)
*
|
2003-12-25 |
2007-08-09 |
Kirin Beer Kabushiki Kaisha |
Stable water-based medicinal preparation containing antibody
|
|
WO2005072772A1
(en)
*
|
2004-01-30 |
2005-08-11 |
Suomen Punainen Risti Veripalvelu |
Pharmaceutical compositions
|
|
BRPI0510915A
(pt)
|
2004-06-04 |
2007-11-13 |
Genentech Inc |
método para o tratamento da esclerose múltipla e artigo manufaturado
|
|
ES2426817T3
(es)
|
2004-08-04 |
2013-10-25 |
Mentrik Biotech, Llc |
Regiones Fc variantes
|
|
TW200621282A
(en)
|
2004-08-13 |
2006-07-01 |
Wyeth Corp |
Stabilizing formulations
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
JP2008523815A
(ja)
|
2004-12-15 |
2008-07-10 |
エラン ファーマ インターナショナル リミテッド |
認知の改善における使用のためのヒト化アミロイドβ抗体
|
|
US7625560B2
(en)
|
2004-12-15 |
2009-12-01 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
|
KR20070107079A
(ko)
*
|
2005-01-28 |
2007-11-06 |
와이어쓰 |
안정화된 액체 폴리펩타이드 제형
|
|
GT200600031A
(es)
|
2005-01-28 |
2006-08-29 |
|
Formulacion anticuerpo anti a beta
|
|
DOP2006000029A
(es)
*
|
2005-02-07 |
2006-08-15 |
Genentech Inc |
Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
|
|
WO2006096461A2
(en)
*
|
2005-03-08 |
2006-09-14 |
Pharmacia & Upjohn Company Llc |
Composition comprising an antibody against macrophage colony-stimulating factor (m-csf) and a chelating agent
|
|
EP1902320B1
(de)
|
2005-05-20 |
2010-03-10 |
Genentech, Inc. |
Vorbehandlung einer biologischen probe aus einem individuum mit autoimmunkrankheit
|
|
JP5089582B2
(ja)
*
|
2005-06-07 |
2012-12-05 |
エスバテック、アン アルコン バイオメディカル リサーチ ユニット、エルエルシー |
ＴＮＦαを阻害する安定な可溶性抗体
|
|
CA2616386A1
(en)
|
2005-07-25 |
2007-02-01 |
Trubion Pharmaceuticals Inc. |
Single dose use of cd20-specific binding molecules
|
|
ES2460517T3
(es)
|
2005-07-25 |
2014-05-13 |
Emergent Product Development Seattle, Llc |
Reducción de células b mediante el uso de moléculas de unión específica a cd37 y de unión específica a cd20
|
|
JP2009503105A
(ja)
*
|
2005-08-03 |
2009-01-29 |
イミュノジェン・インコーポレーテッド |
免疫複合体製剤
|
|
TWI478940B
(zh)
|
2005-08-26 |
2015-04-01 |
Roche Glycart Ag |
具有經改變細胞傳訊活性之改質抗原結合分子
|
|
WO2007036745A2
(en)
|
2005-09-30 |
2007-04-05 |
Medimmune Limited |
Interleukin-13 antibody composition
|
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
|
AU2006318539B2
(en)
|
2005-11-23 |
2012-09-13 |
Genentech, Inc. |
Methods and compositions related to B cell assays
|
|
AR060040A1
(es)
|
2006-03-21 |
2008-05-21 |
Genentech Inc |
Antagonistas de vefg y de alfa5 beta 1
|
|
AU2007229554A1
(en)
*
|
2006-03-28 |
2007-10-04 |
F. Hoffmann-La Roche Ag |
Anti-IGF-1R human monoclonal antibody formulation
|
|
MX2008012896A
(es)
|
2006-04-05 |
2008-10-14 |
Abbott Biotech Ltd |
Purificacion de anticuerpos.
|
|
WO2007120656A2
(en)
|
2006-04-10 |
2007-10-25 |
Abbott Biotechnology Ltd. |
Uses and compositions for treatment of rheumatoid arthritis
|
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
|
EP2839843B1
(de)
|
2006-05-25 |
2018-06-20 |
Biogen MA Inc. |
VLA-1-Antagonisten zur Verwendung bei der Behandlung von Schlaganfall
|
|
EP2418223A3
(de)
|
2006-06-12 |
2013-01-16 |
Emergent Product Development Seattle, LLC |
Einkettige, multivalente Bindungsproteine mit Effektorfunktion
|
|
CA2665567C
(en)
*
|
2006-10-06 |
2012-07-03 |
Amgen Inc. |
Stable formulations
|
|
EP2114451A2
(de)
*
|
2007-01-09 |
2009-11-11 |
Wyeth a Corporation of the State of Delaware |
Anti-il-13-antikörperformulierungen und deren verwendung
|
|
AU2008205512B2
(en)
|
2007-01-16 |
2014-06-12 |
Abbvie Inc. |
Methods for treating psoriasis
|
|
MX2009010361A
(es)
|
2007-03-29 |
2009-10-16 |
Abbott Lab |
Anticuerpos il-12 anti-humanos cristalinos.
|
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
|
WO2008154543A2
(en)
|
2007-06-11 |
2008-12-18 |
Abbott Biotechnology Ltd. |
Methods for treating juvenile idiopathic arthritis
|
|
UA107557C2
(xx)
*
|
2007-07-06 |
2015-01-26 |
|
Композиція антитіла офатумумабу
|
|
MX354993B
(es)
|
2007-07-09 |
2018-03-28 |
Genentech Inc |
Prevención de reducción de enlaces de disulfuro durante la producción recombinante de polipéptidos.
|
|
CA2693611A1
(en)
*
|
2007-07-10 |
2009-01-15 |
F. Hoffmann-La Roche Ag |
Novel formulation
|
|
ES2498040T3
(es)
|
2007-07-27 |
2014-09-24 |
Janssen Alzheimer Immunotherapy |
Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
|
|
JP2011500715A
(ja)
|
2007-10-16 |
2011-01-06 |
ザイモジェネティクス， インコーポレイテッド |
自己免疫疾患の治療のためのＢＬｙＳ阻害剤および抗ＣＤ２０剤の組合せ
|
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
|
WO2009062926A1
(en)
*
|
2007-11-12 |
2009-05-22 |
Ares Trading S.A. |
Taci-immunoglobulin fusion proteins for treatment of relapsing multiple sclerosis
|
|
EP2219675B1
(de)
*
|
2007-11-12 |
2013-10-23 |
Ares Trading S.A. |
Formulierungen für taci-immunoglobulin-fusionsproteine
|
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
|
DK2234600T3
(da)
*
|
2007-12-21 |
2014-09-08 |
Hoffmann La Roche |
Antistofformulering
|
|
EP2077281A1
(de)
|
2008-01-02 |
2009-07-08 |
Bergen Teknologioverforing AS |
Anti-CD20-Antikörper oder Fragmente davon zur Behandlung von chronischen Ermüdungssyndrom
|
|
US7914785B2
(en)
|
2008-01-02 |
2011-03-29 |
Bergen Teknologieverforing As |
B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
|
ES2382058T3
(es)
|
2008-01-17 |
2012-06-04 |
Philogen S.P.A. |
Combinación de una proteína de fusión de un anticuerpo dirigido contra el EDB de la fibronectina-IL-2, y una molécula de unión a los linfocitos B, progenitores de los linfocitos B y/o sus homólogos cancerosos
|
|
PT2132228E
(pt)
|
2008-04-11 |
2011-10-11 |
Emergent Product Dev Seattle |
Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
|
|
TW201438738A
(zh)
|
2008-09-16 |
2014-10-16 |
建南德克公司 |
治療進展型多發性硬化症之方法
|
|
KR20140019035A
(ko)
*
|
2008-09-19 |
2014-02-13 |
에프. 호프만-라 로슈 아게 |
신규한 항체 제형
|
|
EP3228320B1
(de)
|
2008-10-17 |
2019-12-18 |
Sanofi-Aventis Deutschland GmbH |
Kombination von einem insulin und einem glp-1-agonisten
|
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
|
AU2010229479B2
(en)
|
2009-03-25 |
2013-03-28 |
Genentech, Inc. |
Novel anti-alpha5beta1 antibodies and uses thereof
|
|
WO2010146059A2
(en)
|
2009-06-16 |
2010-12-23 |
F. Hoffmann-La Roche Ag |
Biomarkers for igf-1r inhibitor therapy
|
|
EP3202394A1
(de)
|
2009-07-06 |
2017-08-09 |
Sanofi-Aventis Deutschland GmbH |
Wässrige insulinzubereitungen enthaltend methionin
|
|
EP2451844B1
(de)
|
2009-07-10 |
2015-04-22 |
Innate Pharma |
Tlr3-binder
|
|
BR112012002974B1
(pt)
|
2009-08-11 |
2022-06-07 |
Genentech, Inc |
Processo para produzir um anticorpo em uma célula hospedeira de célula ovário de hamster chinês (cho) expressando o referido polipeptídeo
|
|
US8221753B2
(en)
|
2009-09-30 |
2012-07-17 |
Tracon Pharmaceuticals, Inc. |
Endoglin antibodies
|
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
|
US9005926B2
(en)
|
2009-10-02 |
2015-04-14 |
Biogen Idec Ma Inc. |
Methods of preventing and removing trisulfide bonds
|
|
PE20121316A1
(es)
|
2009-11-13 |
2012-10-05 |
Sanofi Aventis Deutschland |
Composicion farmaceutica que comprende un agonista de glp-1 y metionina
|
|
PT2554183T
(pt)
|
2009-11-13 |
2018-07-09 |
Sanofi Aventis Deutschland |
Composição farmacêutica que compreende um agonista de glp-1, uma insulina e metionina
|
|
WO2011100403A1
(en)
|
2010-02-10 |
2011-08-18 |
Immunogen, Inc |
Cd20 antibodies and uses thereof
|
|
CA2803998A1
(en)
*
|
2010-07-02 |
2012-01-05 |
Medimmune, Llc |
Antibody formulations
|
|
JOP20190250A1
(ar)
*
|
2010-07-14 |
2017-06-16 |
Regeneron Pharma |
صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
|
|
FR2962908A1
(fr)
|
2010-07-20 |
2012-01-27 |
Lfb Biotechnologies |
Formulation d'anticorps anti-cd20
|
|
US20140148384A1
(en)
|
2010-08-30 |
2014-05-29 |
Sanofi-Aventis Deutschland Gmbh |
Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
|
|
PL2624865T3
(pl)
*
|
2010-10-06 |
2018-11-30 |
Regeneron Pharmaceuticals, Inc. |
Stabilizowane preparaty zawierające przeciwciała przeciwko receptorowi interleukiny-4 (IL-4R)
|
|
AR083847A1
(es)
|
2010-11-15 |
2013-03-27 |
Novartis Ag |
Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
|
|
WO2012075111A1
(en)
|
2010-11-30 |
2012-06-07 |
Novartis Ag |
Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
|
|
EP2663329A2
(de)
|
2011-01-12 |
2013-11-20 |
Innate Pharma |
Tlr3-binder
|
|
EP2702077A2
(de)
|
2011-04-27 |
2014-03-05 |
AbbVie Inc. |
Verfahren zur steuerung des galactosylierungsprofil von rekombinant exprimierten proteinen
|
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
|
DK2707383T3
(en)
|
2011-05-13 |
2018-07-23 |
Biogen Ma Inc |
PROCEDURES FOR PREVENTION AND REMOVAL OF TRISULPHIDE BINDINGS
|
|
CN108079281A
(zh)
|
2011-08-29 |
2018-05-29 |
赛诺菲-安万特德国有限公司 |
用于2型糖尿病患者中的血糖控制的药物组合
|
|
TWI559929B
(en)
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
|
PE20191242A1
(es)
|
2011-10-25 |
2019-09-16 |
Prothena Biosciences Ltd |
Formulaciones de anticuerpo y metodos
|
|
AU2013212587B2
(en)
|
2012-01-23 |
2017-07-20 |
Regeneron Pharmaceuticals, Inc. |
Stabilized formulations containing anti-Ang2 antibodies
|
|
JP2013147471A
(ja)
*
|
2012-01-23 |
2013-08-01 |
Venture Bank Inc |
ダチョウ抗体水溶液
|
|
JP6345123B2
(ja)
*
|
2012-02-16 |
2018-06-20 |
サンタラス， インコーポレイテッド |
抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物
|
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
|
US9505833B2
(en)
|
2012-04-20 |
2016-11-29 |
Abbvie Inc. |
Human antibodies that bind human TNF-alpha and methods of preparing the same
|
|
US9334319B2
(en)
|
2012-04-20 |
2016-05-10 |
Abbvie Inc. |
Low acidic species compositions
|
|
WO2013176754A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Novel purification of antibodies using hydrophobic interaction chromatography
|
|
AR092325A1
(es)
|
2012-05-31 |
2015-04-15 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
|
|
CN104379603B
(zh)
|
2012-05-31 |
2017-11-07 |
先天制药公司 |
Tlr3结合剂
|
|
US8883979B2
(en)
|
2012-08-31 |
2014-11-11 |
Bayer Healthcare Llc |
Anti-prolactin receptor antibody formulations
|
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
|
HK1211981A1
(en)
|
2012-09-02 |
2016-06-03 |
Abbvie Inc. |
Methods to control protein heterogeneity
|
|
UA115789C2
(uk)
*
|
2012-09-05 |
2017-12-26 |
Трейкон Фармасутікалз, Інк. |
Композиція антитіла до cd105 та її застосування
|
|
AU2013312300A1
(en)
|
2012-09-07 |
2015-04-16 |
Coherus Biosciences, Inc. |
Stable aqueous formulations of adalimumab
|
|
PL2934582T3
(pl)
*
|
2012-12-21 |
2020-08-10 |
Ichnos Sciences SA |
Formulacja przeciwciała anty-her2
|
|
TWI641381B
(zh)
|
2013-02-04 |
2018-11-21 |
法商賽諾菲公司 |
胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
|
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
|
WO2014159579A1
(en)
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
|
|
EP2805730A1
(de)
|
2013-05-21 |
2014-11-26 |
Bergen Teknologioverforing AS |
Stickoxiddonor zur Behandlung des chronischen Ermüdungssyndroms
|
|
WO2015051293A2
(en)
|
2013-10-04 |
2015-04-09 |
Abbvie, Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
|
US20160256460A1
(en)
|
2013-11-01 |
2016-09-08 |
Bergen Teknologioverføring As |
Activators or stimulators of soluble guanylate cyclase for use in treating chronic fatigue syndrome
|
|
JP2014062100A
(ja)
*
|
2013-11-05 |
2014-04-10 |
Glaxosmithkline Llc |
抗体処方
|
|
US20150139988A1
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
|
MX377841B
(es)
|
2013-11-21 |
2025-03-11 |
Genmab As |
Formulación liofilizada de conjugado de anticuerpo-fármaco.
|
|
RU2016132340A
(ru)
|
2014-01-09 |
2018-02-14 |
Санофи |
Стабилизированные фармацевтические составы на основе инсулина аспарта
|
|
KR20160104724A
(ko)
|
2014-01-09 |
2016-09-05 |
사노피 |
인슐린 유사체 및/또는 인슐린 유도체의 안정화된 약제학적 제형
|
|
CN105899191B
(zh)
|
2014-01-09 |
2020-06-16 |
赛诺菲 |
胰岛素类似物和/或胰岛素衍生物的稳定化不含甘油的药物制剂
|
|
EP3148581B1
(de)
|
2014-05-30 |
2019-10-09 |
Henlius Biotech Co., Ltd. |
Anti-egfr-antikörper
|
|
HK1231496A1
(zh)
|
2014-06-20 |
2017-12-22 |
豪夫迈．罗氏有限公司 |
基於chagasin的支架组合物、方法和应用
|
|
US9926375B2
(en)
|
2014-11-12 |
2018-03-27 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
|
WO2016077451A1
(en)
|
2014-11-12 |
2016-05-19 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
|
TWI758239B
(zh)
|
2014-12-12 |
2022-03-21 |
德商賽諾菲阿凡提斯德意志有限公司 |
甘精胰島素/利司那肽固定比率配製劑
|
|
EP3250596A1
(de)
|
2015-01-28 |
2017-12-06 |
Pfizer Inc |
Stabile wässrige antikörperformulierung gegen den vaskulären endothelialen wachstumsfaktor (vegf)
|
|
JP6247241B2
(ja)
*
|
2015-02-27 |
2017-12-13 |
ノバルティス アーゲー |
抗体処方
|
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第２型糖尿病病患治療
|
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第２型糖尿病病患之治療
|
|
RU2021124437A
(ru)
|
2015-04-03 |
2021-09-29 |
Еурека Терапьютикс, Инк. |
Конструкции, направленные на комплексы пептида afp/mhc, и виды их использования
|
|
KR102668727B1
(ko)
|
2015-04-24 |
2024-05-28 |
제넨테크, 인크. |
다중특이적 항원-결합 단백질
|
|
PE20221007A1
(es)
|
2015-06-24 |
2022-06-15 |
Hoffmann La Roche |
Anticuerpos anti-receptor de transferrina con afinidad disenada
|
|
MX2018003292A
(es)
|
2015-09-21 |
2018-08-01 |
Aptevo Res & Development Llc |
Polipéptidos de unión a cd3.
|
|
WO2017055542A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
|
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
|
JP2018529747A
(ja)
|
2015-10-06 |
2018-10-11 |
ジェネンテック， インコーポレイテッド |
多発性硬化症を治療するための方法
|
|
US11229702B1
(en)
|
2015-10-28 |
2022-01-25 |
Coherus Biosciences, Inc. |
High concentration formulations of adalimumab
|
|
JP2019505520A
(ja)
|
2016-01-13 |
2019-02-28 |
ゲンマブ エー／エス |
抗体およびその薬物コンジュゲートの製剤
|
|
US11071782B2
(en)
|
2016-04-20 |
2021-07-27 |
Coherus Biosciences, Inc. |
Method of filling a container with no headspace
|
|
MX2018013683A
(es)
|
2016-05-10 |
2019-06-17 |
Genentech Inc |
Métodos para disminuir los enlaces de trisulfuro durante la producción recombinante de polipéptidos.
|
|
WO2018049275A1
(en)
|
2016-09-09 |
2018-03-15 |
Genentech, Inc. |
Selective peptide inhibitors of frizzled
|
|
ES2977137T3
(es)
|
2016-09-16 |
2024-08-19 |
Shanghai Henlius Biotech Inc |
Anticuerpos anti-PD-1
|
|
US20190374639A1
(en)
|
2016-11-21 |
2019-12-12 |
Polpharma Biologics S.A. |
Aqueous pharmaceutical formulations
|
|
US11274157B2
(en)
|
2017-01-12 |
2022-03-15 |
Eureka Therapeutics, Inc. |
Constructs targeting histone H3 peptide/MHC complexes and uses thereof
|
|
MX420947B
(es)
|
2017-04-26 |
2025-02-10 |
Eureka Therapeutics Inc |
Constructos que reconocen específicamente glipicano 3 y usos de estos.
|
|
MY195465A
(en)
*
|
2017-05-16 |
2023-01-25 |
Jiangsu Hengrui Medicine Co |
PD-L1 Antibody Pharmaceutical Composition and use Thereof
|
|
TWI772488B
(zh)
|
2017-08-08 |
2022-08-01 |
瑞士商赫孚孟拉羅股份公司 |
新穎DLBCL病患次族群之歐比托珠單抗(obinutuzumab)治療
|
|
WO2019177888A1
(en)
|
2018-03-14 |
2019-09-19 |
Boehringer Ingelheim International Gmbh |
Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis
|
|
TWI841554B
(zh)
|
2018-03-21 |
2024-05-11 |
丹麥商珍美寶股份有限公司 |
以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
|
|
CA3099547A1
(en)
|
2018-05-07 |
2019-11-14 |
Reshma Abdulla RANGWALA |
Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
|
|
EP3806904A4
(de)
|
2018-06-18 |
2022-04-27 |
Eureka Therapeutics, Inc. |
Auf prostataspezifisches membranantigen (psma) abzielende konstrukte und verwendungen davon
|
|
WO2020061374A1
(en)
|
2018-09-20 |
2020-03-26 |
Mandalmed, Inc. |
Methods and compositions for preventing, treating, and reversing liver fibrosis
|
|
TWI844571B
(zh)
|
2018-10-30 |
2024-06-11 |
丹麥商珍美寶股份有限公司 |
使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
|
|
EP4640698A3
(de)
|
2018-11-16 |
2026-02-25 |
Memorial Sloan Kettering Cancer Center |
Antikörper gegen mucin-16 und verfahren zu ihrer verwendung
|
|
CA3183309A1
(en)
|
2018-11-27 |
2020-06-04 |
Staidson (Beijing) Biopharmaceuticals Co., Ltd. |
Antibodies specifically recognizing granulocyte-macrophage colony stimulating factor receptor alpha and uses thereof
|
|
KR20210137520A
(ko)
*
|
2019-03-08 |
2021-11-17 |
베링거 인겔하임 인터내셔날 게엠베하 |
항-il-36r 항체 제형
|
|
RU2754760C2
(ru)
*
|
2019-04-02 |
2021-09-07 |
Закрытое Акционерное Общество "Биокад" |
Водная фармацевтическая композиция анти-il17a антитела и ее применение
|
|
WO2021004446A1
(en)
|
2019-07-09 |
2021-01-14 |
Staidson (Beijing) Biopharmaceuticals Co., Ltd. |
Antibodies specifically recognizing pseudomonas pcrv and uses thereof
|
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
|
EP4021457A1
(de)
|
2019-08-30 |
2022-07-06 |
Vestlandets Innovasjonsselskap AS |
Verfahren zur behandlung von chronischem ermüdungssyndrom unter verwendung eines hemmenden oder cytotoxischen mittels gegen plasmazellen
|
|
CA3182697A1
(en)
|
2020-05-11 |
2021-11-18 |
Janssen Biotech, Inc. |
Methods for treating multiple myeloma
|
|
EP4157881A4
(de)
|
2020-05-27 |
2024-10-09 |
Staidson (Beijing) Biopharmaceuticals Co., Ltd. |
Antikörper, die spezifisch den nervenwachstumsfaktor erkennen, und deren verwendungen
|
|
JP7812364B2
(ja)
|
2020-07-17 |
2026-02-09 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
好中球性皮膚症の処置のための抗ｉｌ－３６ｒ抗体
|
|
JP2023537751A
(ja)
|
2020-08-14 |
2023-09-05 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
オクレリズマブで多発性硬化症を治療するための方法
|
|
US20250011448A1
(en)
|
2021-07-08 |
2025-01-09 |
Staidson Biopharma Inc. |
Antibodies specifically recognizing tnfr2 and uses thereof
|
|
WO2023284714A1
(zh)
|
2021-07-14 |
2023-01-19 |
舒泰神（北京）生物制药股份有限公司 |
特异性识别cd40的抗体及其应用
|
|
KR20240099376A
(ko)
|
2021-11-03 |
2024-06-28 |
얀센 바이오테크 인코포레이티드 |
암 치료 및 bcmaxcd3 이중특이성 항체의 효능을 향상시키는 방법
|
|
JP2024544523A
(ja)
*
|
2021-11-10 |
2024-12-03 |
ヤンセン バイオテツク，インコーポレーテツド |
二重特異性ｂｃｍａ／ｃｄ３抗体を含む安定な製剤
|
|
IL312692A
(en)
|
2021-11-16 |
2024-07-01 |
Genentech Inc |
Methods and compositions for the treatment of systemic lupus erythematosus (SLE) with musontuzumab
|
|
EP4445911A4
(de)
|
2021-12-06 |
2025-10-22 |
Beijing Solobio Genetechnology Co Ltd |
Bispezifischer antikörper mit spezifischer bindung an klebsiella pneumoniae-o2- und o1-antigene sowie zusammensetzung
|
|
US12122850B2
(en)
|
2022-03-14 |
2024-10-22 |
LamKap Bio gamma AG |
Bispecific GPC3xCD28 and GPC3xCD3 antibodies and their combination for targeted killing of GPC3 positive malignant cells
|
|
CN119487065A
(zh)
|
2022-05-09 |
2025-02-18 |
舒泰神（北京）生物制药股份有限公司 |
特异性识别gdf15的抗体及其应用
|
|
WO2024020407A1
(en)
|
2022-07-19 |
2024-01-25 |
Staidson Biopharma Inc. |
Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
|
|
WO2024067344A1
(zh)
|
2022-09-27 |
2024-04-04 |
舒泰神（北京）生物制药股份有限公司 |
特异性识别light的抗体及其应用
|
|
KR20250093362A
(ko)
|
2022-10-20 |
2025-06-24 |
베이징 솔로바이오 진테크놀로지 컴퍼니 리미티드 |
TRAIL 또는 FasL에 특이적으로 결합하는 항체 조합 및 이중특이 항체
|
|
CN121311247A
(zh)
|
2023-06-09 |
2026-01-09 |
舒泰神（北京）生物制药股份有限公司 |
特异性结合masp3的抗体以及特异性结合masp3和masp2的多特异性抗体
|
|
CN121358781A
(zh)
|
2023-06-16 |
2026-01-16 |
江苏贝捷泰生物科技有限公司 |
特异性识别因子XIIa的抗体及其应用
|
|
TW202517294A
(zh)
|
2023-07-11 |
2025-05-01 |
美商建南德克公司 |
用於治療多發性硬化症之組成物及方法
|